Satellos Bioscience Inc. Expense From Share-based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets
Satellos Bioscience Inc. (MSLE) reported Expense From Share-based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets of $3.23 million for the 12-month period ending 2025-12-31, per its 40-F filed 2026-03-27.
Financial Statements › Expense Statement › Operating Expenses
ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets · last filed 2026-03-27
| Period end | Expense From Share-based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets 12 month |
|---|---|
| 2025-12-31 | $3.23M 40-F · filed 2026-03-27 |
| 2024-12-31 | $1.64M 40-F · filed 2026-03-27 |